Arcellx, Inc. (NASDAQ:ACLX) Holdings Cut by Samsara BioCapital LLC

Samsara BioCapital LLC lessened its holdings in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 28.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 253,641 shares of the company's stock after selling 100,000 shares during the period. Arcellx comprises 2.6% of Samsara BioCapital LLC's holdings, making the stock its 9th biggest position. Samsara BioCapital LLC owned 0.47% of Arcellx worth $19,452,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Xponance Inc. increased its stake in Arcellx by 8.6% during the 4th quarter. Xponance Inc. now owns 3,088 shares of the company's stock valued at $237,000 after purchasing an additional 244 shares in the last quarter. KBC Group NV grew its position in shares of Arcellx by 37.3% in the fourth quarter. KBC Group NV now owns 1,388 shares of the company's stock valued at $106,000 after purchasing an additional 377 shares in the last quarter. Swiss National Bank raised its stake in Arcellx by 0.8% during the fourth quarter. Swiss National Bank now owns 63,400 shares of the company's stock worth $4,862,000 after purchasing an additional 500 shares during the period. Headlands Technologies LLC purchased a new position in Arcellx in the fourth quarter worth approximately $41,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Arcellx by 9.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,836 shares of the company's stock worth $754,000 after acquiring an additional 858 shares during the last quarter. Hedge funds and other institutional investors own 96.03% of the company's stock.

Insider Activity

In related news, Director Kavita Patel sold 1,500 shares of the stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $64.20, for a total transaction of $96,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher Heery sold 10,155 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $63.79, for a total transaction of $647,787.45. Following the completion of the transaction, the insider now owns 37,486 shares of the company's stock, valued at $2,391,231.94. This represents a 21.32 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,955 shares of company stock worth $3,504,758. 6.24% of the stock is currently owned by insiders.

Arcellx Stock Performance

Shares of Arcellx stock traded down $0.79 during trading hours on Monday, hitting $64.77. The company's stock had a trading volume of 70,594 shares, compared to its average volume of 552,341. The firm has a fifty day moving average of $64.90 and a 200-day moving average of $73.77. The stock has a market cap of $3.57 billion, a price-to-earnings ratio of -90.96 and a beta of 0.33. Arcellx, Inc. has a twelve month low of $47.88 and a twelve month high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The company had revenue of $15.27 million for the quarter, compared to analysts' expectations of $27.42 million. On average, sell-side analysts expect that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).